Plain-English translation of NCT04528355 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a study following patients who are receiving stem cell transplants using a newer, gentler conditioning regimen that combines alemtuzumab, hydroxyurea, fludarabine, melphalan, and thiotepa. Researchers want to track how well this treatment works, how quickly patients recover, and whether the new stem cells successfully take hold in the body.
Gentler conditioning regimens promise to reduce serious side effects from transplant treatment, but doctors want to better understand how well this particular medication combination prevents graft failure and infections while keeping patients healthy long-term.
You likely qualify if…
You likely don't qualify if…
You will undergo a stem cell transplant using the gentler conditioning regimen as part of your regular medical care at UPMC Children's Hospital of Pittsburgh. Researchers will collect information from your medical records over time, tracking your recovery, how well your new stem cells engraft, any graft-versus-host disease, your use of immune-suppressing medications, and your overall survival and quality of life.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Enrollment target
~50 participants
Started
August 2020
Primary completion
December 2027
Age range
2 Months – 60 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Paul Szabolcs, MD
UPMC Children's Hospital of Pittsburgh
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.